Omitting of Lymphadenectomy is Acceptable for Lung Cancer Smaller Than 6 mm in Solid Size

NCT06516796 | Completed

• 1 other identifier: 2022-SR-760
• Study Type: observational
• Target: 2,713
• Locations: 1 country
• Sites: 1

Brief Summary

Many studies suggested that selective lymph node sampling was acceptable for specific non-small cell lung cancer (NSCLC). This study aimed to evaluate the acceptability of omitting of lymphadenectomy for selected NSCLC. Patients with small-sized (≤2 cm) NSCLC who underwent surgical resection between 2009 and 2022 were retrospectively screened.

Conditions

Non-small Cell Lung Cancer

Keywords

Sublobar resection; Non-small cell lung cancer; No lymphadenectomy; Solid size

Outcome Measures

Primary Outcomes (1)

• Overall survival (OS)

  OS was defined from the surgical date to the date of death or the date of the last follow-up. defined from the surgical date to the date of death or the date of the last follow-up.

  OS was defined from the surgical date to the date of death or the date of the last follow-up, whichever came first, assessed up to 14 years.

Study Arms (3)

sublobar resection without lymphadenectomy

Patients received sublobar resection but had no lymphadenectomy

Other: No intervention

sublobar resection with lymphadenectomy

Patients received sublobar resection plus lymphadenectomy

Other: No intervention

lobectomy plus lymphadenectomy

Patients received lobectomy plus lymphadenectomy

Other: No intervention

Interventions

No intervention OTHER

Patients were retrospectively screened.

lobectomy plus lymphadenectomy; sublobar resection with lymphadenectomy; sublobar resection without lymphadenectomy

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Non-small cell lung cancer with a total tumor size within 2 cm

You may qualify if:

• pathologically confirmed non-small cell lung cancer (NSCLC)
• the maximum tumor diameter ≤2 cm
• receiving surgical treatment between 2009-2022

You may not qualify if:

• non-primary NSCLC;
• with small cell lung cancer components;
• undergoing preoperative neoadjuvant therapies;
• with compromised resection;
• malignant tumor history over the past five years.

Sponsors & Collaborators

• Liang Chen: lead

Study Sites (1)

Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, 210029, China

Location

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Liang Chen, MD

  The First Affiliated Hospital with Nanjing Medical University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Director, Head of Thoracic Surgery

Study Record Dates

• First Submitted: July 17, 2024
• First Posted: July 24, 2024
• Study Start: January 1, 2023
• Primary Completion: January 1, 2024
• Study Completion: February 1, 2024
• Last Updated: July 24, 2024

Record last verified: 2024-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)